AC Immune (NASDAQ:ACIU) Stock Price Passes Below Fifty Day Moving Average – Here’s Why

AC Immune (NASDAQ:ACIU)’s stock price crossed below its 50 day moving average during trading on Tuesday . The stock has a 50 day moving average of $3.00 and traded as low as $2.59. AC Immune shares last traded at $2.75, with a volume of 127,564 shares changing hands.

Analyst Ratings Changes

ACIU has been the topic of a number of analyst reports. BTIG Research reiterated a “buy” rating and set a $8.00 price objective on shares of AC Immune in a research note on Monday, March 16th. Jefferies Financial Group reaffirmed a “buy” rating and set a $7.00 price target on shares of AC Immune in a report on Friday, March 13th. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of AC Immune in a research note on Wednesday, January 21st. Finally, Wall Street Zen upgraded shares of AC Immune from a “sell” rating to a “hold” rating in a report on Saturday, February 28th. Three analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has assigned a Sell rating to the company. According to data from MarketBeat, the stock currently has a consensus rating of “Hold” and an average target price of $9.00.

AC Immune Trading Up 7.4%

The business has a 50 day simple moving average of $3.00 and a two-hundred day simple moving average of $3.09. The stock has a market cap of $279.87 million, a price-to-earnings ratio of -3.27 and a beta of 1.64.

AC Immune (NASDAQ:ACIU) last announced its earnings results on Friday, March 13th. The company reported ($0.18) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.19) by $0.01. The company had revenue of $0.44 million for the quarter, compared to analyst estimates of $1.14 million. AC Immune had a negative return on equity of 103.15% and a negative net margin of 1,977.71%. Research analysts anticipate that AC Immune will post -0.62 EPS for the current fiscal year.

Institutional Inflows and Outflows

A number of large investors have recently added to or reduced their stakes in the stock. EFG International AG bought a new stake in shares of AC Immune in the 4th quarter worth about $41,000. Marshall Wace LLP acquired a new stake in shares of AC Immune during the fourth quarter worth $586,000. Dimensional Fund Advisors LP raised its holdings in shares of AC Immune by 20.5% during the fourth quarter. Dimensional Fund Advisors LP now owns 213,464 shares of the company’s stock worth $670,000 after purchasing an additional 36,353 shares during the period. Goldman Sachs Group Inc. lifted its position in shares of AC Immune by 46.9% in the 4th quarter. Goldman Sachs Group Inc. now owns 18,555 shares of the company’s stock worth $58,000 after buying an additional 5,920 shares during the last quarter. Finally, Susquehanna International Group LLP bought a new position in shares of AC Immune in the 3rd quarter worth about $63,000. 51.36% of the stock is currently owned by institutional investors.

AC Immune Company Profile

AC Immune AG is a clinical-stage biopharmaceutical company headquartered in Lausanne, Switzerland, with a subsidiary in Boston, Massachusetts. The company specializes in the discovery and development of therapeutics and diagnostics for neurodegenerative diseases, with a primary focus on Alzheimer’s disease, Parkinson’s disease and other protein misfolding disorders. AC Immune leverages proprietary platform technologies to identify and optimize candidates that target pathological protein aggregates.

Since its founding in 2003, AC Immune has advanced multiple programs into clinical development.